Among metabolic agents, drugs used to treat diabetes early in the course of disease (e.g., metformin as a first line treatment) had higher rates of overall use but lower rates of co-prescription relative to treatments that tend to be prescribed concomitantly later in the disease course (e.g., thiazolidinediones and insulin; Fig. 2B). The gene discussed is INS; the disease is diabetes mellitus.